Dual-marker algorithm better predicts risk for ovarian cancer

Article

A novel multiple marker assay that uses serum HE4 and CA125 to calculate a risk of ovarian malignancy algorithm better predicts epithelial ovarian cancer in women with pelvic masses than the risk of malignancy index, according to recent research.

A novel multiple marker assay that uses serum HE4 and CA125 to calculate a Risk of Ovarian Malignancy Algorithm (ROMA) better predicts epithelial ovarian cancer in women with pelvic masses than the Risk of Malignancy Index (RMI), according to recently published research.

Researchers included in their study 457 women with an identified pelvic mass or ovarian cyst and planned surgical intervention. They determined RMI values using CA125, imaging score, and menopausal status and established ROMA values using HE4, CA125, and menopausal status.

The researchers found that the sensitivity for distinguishing benign masses from cancerous lesions was 94.3% for ROMA and 84.6% for RMI (P=.0029) at a set specificity of 75%. For women with stage I or II disease, sensitivities were 85.3% and 64.7%, respectively (P<.0001).

Related Videos
Study unveils maternal mortality tracking trends | Image Credit: obhg.com
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit: hyperemesis.org
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
© 2024 MJH Life Sciences

All rights reserved.